L-Lysine escinate® (L-lysine aescinat® )

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceEscin lysinateEscin lysinate
Similar drugsTo uncover
  • L-Lysine escinate®
    concentrate in / in 
    GALICHFARM, PAO     Ukraine
    • Dosage form: & nbspconcentrate for solution for intravenous administration
    Composition:

    1 ml of the preparation contains:

    active substance: L-lysine escinate, in terms of 100% of the substance, 1.0 mg;

    Excipients: ethanol (ethyl alcohol) 96% 200.0 mg, propylene glycol 200.0 mg, water for injection up to 1 ml.

    Description:Transparent colorless or slightly yellowish solution.
    Pharmacotherapeutic group:angioprotective agent
    ATX: & nbsp

    C.05.C.X   Other drugs that reduce the permeability of capillaries

    Pharmacodynamics:

    Llysine escinate reduces the activity of lysosomal hydrolases, which prevents cleavage of mucopolysaccharides in the walls of the capillaries and in the connective tissue that surrounds them, and thus normalizes the increased vascular-tissue permeability and exerts an antiexudative (anti-edema) and analgesic effect. The drug increases the tone of the vessels, has a moderate hypoglycemic effect.

    Pharmacokinetics:Not studied.
    Indications:

    - Post-traumatic and postoperative swelling of soft tissues of different localization;

    - edema of the brain or spinal cord of traumatic or postoperative origin;

    - violations of peripheral venous circulation, accompanied by edema.

    Contraindications:

    - Hypersensitivity to Llysine escinate and / or other components of the preparation;

    - severe renal dysfunction;

    - severe violations of liver function;

    - bleeding;

    - children's age till 18 years;

    - pregnancy;

    - the period of breastfeeding.

    Dosing and Administration:

    The drug is administered strictly intravenously slowly, as a rule, drip (intra-arterial administration is not allowed!) In a daily dose of 5-10 ml.

    For the preparation of infusion solution L-lysine escinate® is diluted in 50-100 ml of a 0.9% solution of sodium chloride. If necessary, the drug can be administered intravenously struino very slowly.

    DFor intravenous fluid administration L-lysine escinate ® is diluted in 10-15 ml of 0.9% sodium chloride solution. Without prior dilution, the drug is not used.

    In conditions that threaten the patient's life (craniocerebral trauma, postoperative swelling of the brain and spinal cord with swelling-swelling phenomena, swelling of large sizes due to extensive injuries of soft tissues), the daily dose is increased to 20 ml, divided into 2 doses.

    The duration of the course of treatment is from 2 to 8 days, depending on the patient's condition and the effectiveness of therapy.

    Side effects:

    With individual hypersensitivity to escin, individual patients are able to:

    - allergic reactions: skin rash (papular, petechial, erythematous), itching, flushing of the facial skin, lips, fever, urticaria, in rare cases - angioedema, anaphylactic shock;

    - from the central and peripheral nervous system: headache, dizziness, tremor, in isolated cases - ataxia, short-term loss of consciousness;

    - from the liver and biliary system: increased activity of transaminases and bilirubin;

    - from the gastrointestinal tract: nausea, in rare cases - vomiting, diarrhea;

    - from the cardiovascular system: lowering blood pressure (hypotension), increasing blood pressure (hypertension), tachycardia, chest pain;

    - on the part of the respiratory system: single cases - a feeling of lack of air, dyspnea, bronchial obstruction, dry cough;

    - local reactions: burning along the vein with the introduction, phlebitis, pain in the hand;

    - other: general weakness, chills, fever.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.
    Overdose:

    Symptoms: fever, tachycardia, nausea, heartburn, epigastric pain.

    Treatment: symptomatic therapy.
    Interaction:

    The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity.

    In the case of a recent, prior appointment L-lysine escinate® for prolonged therapy with anticoagulants or when simultaneous administration is required Llysine escinate ® and anticoagulants, it is necessary to correct the dose of the latter under the control of the prothrombin index.

    The binding of escin to plasma proteins is hampered by the simultaneous use of antibiotics of the cephalosporin series, which can increase the concentration of free escin in the blood with the risk of developing side effects of the latter.

    The composition of the drug includes ethyl alcohol 96%. It is necessary to take into account the possible interaction of alcohol with other medicinal products.

    Special instructions:

    In some patients with hepatocholecystitis, a short-term increase in the administration of the drugactivity of transaminases and bilirubin (direct fraction), which do not pose a threat to patients and do not require the withdrawal of the drug.

    The concentrate for the preparation of the solution for intravenous administration contains bulk 23.8% of ethanol, that is, up to 2.4 ml of ethanol in a single dose and up to a maximum of 6.1 ml per day, corresponding to 122 ml of beer or 50.8 ml of wine per day.

    The drug should be prescribed with caution in alcoholism, as well as patients with liver disease and epilepsy.

    Effect on the ability to drive transp. cf. and fur:The use of the drug may affect the ability to drive vehicles and mechanisms, but due to the severity of injuries in which the application is shown, this factor usually does not matter.
    Form release / dosage:Concentrate for the preparation of a solution for intravenous administration, 1 mg / ml.
    Packaging:

    5 ml per ampoule with a kink ring yellow or with a break point, or without a ring and a point.

    5 ampoules are put in a contour mesh package made of a polyvinyl chloride film or in a contour cell package made of a polyvinyl chloride film, film-coated Pheat-sealing olive.

    Two contour cell packs together with the instructions for use and the ampoule scarifier are put in a pack.

    When using ampoules with a break point or a fracture ring, the scarifier is not put into the pack.

    Storage conditions:

    Store in a dark place at a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000504
    Date of registration:01.03.2011 / 05.02.2016
    Expiration Date:01.03.2016
    Date of cancellation:2016-03-01
    The owner of the registration certificate:GALICHFARM, PAO GALICHFARM, PAO Ukraine
    Manufacturer: & nbsp
    Information update date: & nbsp03.10.2015
    Illustrated instructions
      Instructions
      Up